NatCure Sciences (NatCure) is a privately held start-up biopharmaceutical company designed to identify specialty natural products with medicinal properties and develop pharmaceuticals to treat human and animal diseases in an intensely capital efficient business model.  The company's lead product NAT-100 is derived from a natural plant (African Tree Bark) extract with demonstrated anti-inflammatory and immunosuppressive activity.  It will be developed as a new molecular entity (NME) to treat autoimmune diseases such as Inflammatory Bowel Disorder (IBD)/ Crohn's disease and Multiple Sclerosis (MS).  These are multi-billion dollar markets with large unmet need.  The current products are either toxic or demonstrate significant side effects from short-term or long-term usage that could include symptoms like flushing, chest pain, pounding heartbeat, anxiety, trouble breathing, closing of the throat, and hives.  These include beta interferon, azathioprine, cyclosporine, tacrolimus, copaxone and corticosteroids like hydrocortisone and prednisone.  NAT-100 is expected to be disease modifying with minimal safety issues, due to its natural plant origins and centuries of medicinal use.  According to a 2010 Decision Resources report, in the U.S. and Japan, the prevalence of Crohn's was 585,000 patients.  Prevalence rates for these and all autoimmune disorders are expected to continue to rise in the next several years.

Business plan for NATCURE SCIENCES, INC

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.